The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 333:823-831 September 28, 1995 Number 13
NextNext

A Controlled Study of Adenoviral-Vector–Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis
Michael R. Knowles, M.D., Kathy W. Hohneker, R.N., Zhaoqing Zhou, Ph.D., John C. Olsen, Ph.D., Terry L. Noah, M.D., Ping-Chuan Hu, Ph.D., Margaret W. Leigh, M.D., John F. Engelhardt, Ph.D., Lloyd J. Edwards, Ph.D., Kim R. Jones, M.D., Ph.D., Mariann Grossman, B.S., James M. Wilson, M.D., Ph.D., Larry G. Johnson, M.D., and Richard C. Boucher, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Cystic fibrosis is a monogenic disease that deranges multiple systems of ion transport in the airways, culminating in chronic infection and destruction of the lung. The introduction of a normal copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the airway epithelium through gene transfer is an attractive approach to correcting the underlying defects in patients with cystic fibrosis. We tested the feasibility of gene therapy using adenoviral vectors in the nasal epithelium of such patients.

Methods An adenoviral vector containing the normal CFTR complementary DNA in four logarithmically increasing doses (estimated multiplicity of infection, 1, 10, 100, and 1000), or vehicle alone, was administered in a randomized, blinded fashion to the nasal epithelium of 12 patients with cystic fibrosis. Gene transfer was quantitated by molecular techniques that detected the expression of CFTR messenger RNA and by functional measurements of transepithelial potential differences (PDs) to assess abnormalities of ion transport specific to cystic fibrosis. The safety of this treatment was monitored by nasal lavage and biopsy to assess inflammation and vector replication.

Results The adenoviral vector was detected in nasal-lavage fluid by culture, the polymerase chain reaction (PCR), or both in a dose-dependent fashion for up to eight days after vector administration. There was molecular evidence of gene transfer by reverse-transcriptase PCR assays or in situ hybridization in five of six patients treated at the two highest doses. However, the percentage of epithelial cells transfected by the vector was very low (<1 percent), and measurement of PD across the epithelium revealed no significant restoration of chloride transport or normalization of sodium transport. At the lower doses of vector, there were no toxic effects. However, at the highest dose there was mucosal inflammation in two of three patients.

Conclusions In patients with cystic fibrosis, adenoviral-vector–mediated transfer of the CFTR gene did not correct functional defects in nasal epithelium, and local inflammatory responses limited the dose of adenovirus that could be administered to overcome the inefficiency of gene transfer.


Source Information

From the Department of Medicine, Cystic Fibrosis–Pulmonary Research and Treatment Center (M.R.K., K.W.H., Z.Z., J.C.O., K.R.J., L.G.J., R.C.B.), and the Departments of Pediatrics (T.L.N., P.-C.H., M.W.L.) and Biostatistics (L.J.E.), School of Public Health, University of North Carolina, Chapel Hill; and the Institute for Human Gene Therapy and the Department of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia (J.F.E., M.G., J.M.W.).

Address reprint requests to Dr. Knowles at the Cystic Fibrosis–Pulmonary Research and Treatment Center, 724 Burnett–Womack Bldg., CB 7020, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7020.

Full Text of this Article


Related Letters:

Gene Therapy
Alton E., Geddes D. M., Wagner J. A., Knowles M., Boucher R.
Extract | Full Text  
N Engl J Med 1996; 334:332-333, Feb 1, 1996. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.